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The Neuropeptide S system, consisting of the 20-amino acid peptide neuropeptide S
(NPS) and its G-protein coupled receptor (NPSR), modulates arousal, wakefulness,
anxiety, and fear-extinction in mice. In addition, recent evidence indicates that the
NPS system attenuates stress-dependent impairment of fear extinction, and that
NPS-expressing neurons in close proximity to the locus coeruleus region (LC;
pericoerulear, periLC) are activated by stress. Furthermore, periLC NPS neurons receive
afferents from neurons of the centrolateral nucleus of the amygdala (CeL), of which
a substantial population expresses the kappa opioid receptor (KOR) ligand precursor
prodynorphin. This study aims to identify the effect of the dynorphinergic system on NPS
neurons in the periLC via pre- and postsynaptic mechanisms. Using electrophysiological
recordings in mouse brain slices, we provide evidence that NPS neurons in the
periLC region are directly inhibited by dynorphin A (DynA) via activation of κ-opioid
receptor 1 (KOR1) and a subsequent increase of potassium conductances. Thus, the
dynorphinergic system is suited to inactivate NPS neurons in the periLC. In addition
to this direct, somatic effect, DynA reduces the efficacy of GABAergic synapses on
NPS neurons via KOR1 and KOR2. In conclusion, the present study provides evidence
for the interaction of the NPS and the kappa opioid system in the periLC. Therefore,
the endogenous opioid dynorphin is suited to inhibit NPS neurons with a subsequent
decrease in NPS release in putative target regions leading to a variety of physiological
consequences such as increased anxiety or vulnerability to stress exposure.
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INTRODUCTION
The neuropeptide S (NPS) system, consisting of the 20-amino acid peptide NPS and its
G-protein coupled receptor (NPSR), has been shown to be involved in processes of anxiety,
fear-extinction, and fear memory consolidation (Xu et al., 2004; Okamura and Reinscheid,
2007; Jüngling et al., 2008; Okamura et al., 2011). Recent evidence suggests that the NPS
system is involved in stress coping and that stressful events increase the release of NPS
in the amygdala of rodents (Ebner et al., 2011; Chauveau et al., 2012). In line with this,
immobilization stress induces an up-regulation of c-fos in NPS-expressing neurons, indicating
an activation of these neurons during periods of stress (Liu et al., 2011; Jüngling et al., 2012).
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The NPS neurons express the corticotropin-releasing factor
receptor 1 (CRF1) and depolarize following CRF1 activation by
CRF or stressin I (Liu et al., 2011; Jüngling et al., 2012).
Stressful conditions additionally promote the activation of
endogenous opioid systems (for review, Knoll and Carlezon,
2010) and the release of dynorphin A (DynA), which in
turn activates κ-opioid receptors (KOR; Chavkin et al., 1982).
Activation of the dynorphin system induces analgesia, but also
aversive and prodepressive-like behavior in rodents (Mague
et al., 2003; Carlezon et al., 2006; Bruchas et al., 2007; Land
et al., 2008, 2009; Knoll and Carlezon, 2010). The activation
of KORs has been shown to modulate the excitability of
neurons and directly influence transmitter release by presynaptic
mechanisms. Depending on the cell type and brain region,
dynorphin can either increase or decrease the activity of neurons.
An increase in activity can be based on e.g., the enhancement
of a hyperpolarization-activated current (Ih; Pan, 2003) or
on the modulation of voltage-dependent potassium currents
(McDermott and Schrader, 2011). In contrast, a decrease
in neuronal activity can be mediated by an enhancement
of potassium conductances, most likely inwardly rectifying
potassium conductances (Grudt and Williams, 1993, 1995;
Ma et al., 1995). In rodents, agonists of KORs attenuate
the release of various neurotransmitters and neuropeptides
on the norepinephrine neurons of the locus coeruleus (LC)
by presynaptic inhibition (Kreibich et al., 2008). Neurons of
the LC receive afferents from the central amygdala (Dimitrov
et al., 2013) and these afferents can contain CRF and/or
dynorphin (Reyes et al., 2008, 2011). NPS-expressing neurons
in the periLC region have recently been shown to receive
central amygdalar afferents originating from dynorphin- and
somatostatin-expressing neurons (Jüngling et al., 2015). In
addition, NPS neurons are inactivated by application of
DynA or somatostatin, indicating a negative control of NPS-
expressing neurons by these peptide systems (Jüngling et al.,
2015).
Based on the findings that the NPS system is involved in
stress responses and that NPS neurons in the periLC respond
to CRF and DynA, two key players of stress responses, we used
in vitro slice electrophysiology to analyze the effects of DynA
on NPS neurons in more detail and to identify the underlying
synaptic mechanisms. In addition to the direct inhibitory effect
of DynA on NPS neurons, we analyzed its role in the regulation
of synaptic efficacy of GABAergic afferents projecting onto NPS
neurons.
MATERIALS AND METHODS
Animals
Heterozygous transgenic mice expressing the enhanced green
fluorescent protein (EGFP) under the control of the NPS
promotor (transgenic NPS-EGFP mouse line E16; Liu et al.,
2011) were bred with C57Bl/6 mice and offspring was genotyped
by PCR as described previously (Liu et al., 2011). Mice were
kept in a temperature (21◦C) and humidity-controlled (50–60%
relative humidity) animal facility with access to food and
water ad libitum and a 12:12 h light-dark cycle with lights
on at 6:00 AM. All animal experiments were carried out in
accordance with national regulations on animal experimentation
(European Committees Council Directive 86/609/EEC; National
Research Council of the National Academies) and protocols were
approved by the local authorities (Bezirksregierung Münster, AZ
50.0835.1.0, G 53/2005) and ‘‘Landesamt für Natur, Umwelt und
Verbraucherschutz Nordrhein-Westfalen’’ (reference number:
8.87-51.05.20.10.218).
Electrophysiology
Six to ten weeks old NPS-EGFP mice of either sex
were anesthetized with isoflurane (Forene, 1-Chloro-2,2,
2-trifluoroethyl-difluoromethylether; 2.5%) and killed by
decapitation. Horizontal slices (300 µm thick) containing the
LC were prepared. Whole-cell patch-clamp recordings (in
voltage- or current-clamp mode) were performed as described
previously (Jüngling et al., 2008).We used patch pipettes made of
borosilicate glass (GC150T-10, Harvard Apparatus, Edenbridge),
pulled on a vertical puller (PA-10, E.S.F. Electronic, Germany).
The intracellular solution used to analyze the intrinsic properties
of NPS-EGFP neurons contained [in mM]: NaCl 10, K-gluconate
105, K3-citrate 20, HEPES 10, BAPTA 3, MgCl2 1, MgATP 3, and
NaGTP 0.5. The pH was adjusted to 7.25. Artificial cerebrospinal
fluid (aCSF) was used as extracellular solution and contained
[in mM]: NaCl 120, KCl 2.5, NaH2PO4 1.25, MgSO4 2, CaCl2
2, and glucose 20. The pH was adjusted to 7.3 by gassing with
carbogen (95% O2, 5% CO2). The liquid junction potential was
corrected for (10 mV). The pipette resistance was between 2.2
and 2.8 MΩ using the intracellular solution listed above. The
series resistance RS was between 5–15 MΩ and recordings with
higher RS were rejected from analysis. All experiments were
performed at 30–32◦C.
Active and passive membrane properties were assessed during
whole-cell current-clamp recordings at a membrane potential of
−60 mV. Hyper- and depolarizing currents were injected for
500 ms (injected currents from −80 to +140 pA; ∆I +10 pA).
Active membrane properties were analyzed during depolarizing
current injections of +80 to +120 pA. The input resistance of
the recorded neurons was calculated by Rinput − ∆V/I. ∆V
was determined under steady-state conditions at the end of
an injected hyperpolarizing current pulse (I = −50 pA). The
membrane time constant τ was obtained by a monoexponential
fit of the membrane potential shift. The resting membrane
potential wasmeasured immediately after establishing the whole-
cell configuration. The after-hyperpolarizing potential (AHP)
was determined after the first action potential (AP). The slow
AHP (sAHP) was defined as hyperpolarizing voltage deflection
following a 500 ms current injection of +80 pA. The AP half-
width was extracted from the first AP. The time-to-first-AP was
calculated as time from the beginning of the depolarizing current
injection (+80 pA) to the onset of the first AP. The instantaneous
frequency was calculated between the first two APs occurring in
response to a depolarizing current injection of +80 pA.
Electrophysiological data were acquired with an
EPC10-double amplifier (HEKA, Germany) at a sampling
Frontiers in Cellular Neuroscience | www.frontiersin.org 2 March 2016 | Volume 10 | Article 61
Jüengling et al. Neuropeptide S and Dynorphin
rate of 10 kHz and analyzed offline with Clampfit10 software
(Molecular Devices Corporation, Sunnyvale, CA, USA).
Drug Testing
To analyze the effect of opioid receptor agonists, NPS-EGFP
neurons were recorded either in the current-clamp mode at a
membrane potential around −65 mV or in the voltage-clamp
mode at −65 mV. Drugs were bath-applied for 5 min at a
perfusion speed of ∼3.5 ml/min. In the current-clamp mode,
the input resistance was monitored by injecting hyperpolarizing
currents of −50 pA. During maximal drug effect, the membrane
potential was manually set to baseline values by adjusting
a DC offset to exclude changes of the input resistance
induced by voltage-dependent conductances. Gabazine (GBZ;
25 µm) or picrotoxin (100 µm), CGP55845 (10 µm),
D-(-)-2-Amino-5-phosphonopentanoic acid (AP5, 50 µm), and
6,7-Dinitroquinoxaline-2,3-dione (DNQX, 10 µm) were added
to the bathing solution as required to block GABAergic
and glutamatergic postsynaptic currents, respectively. In some
experiments, tetrodotoxin (TTX, 0.5–1 µm) was added to
decrease network activity (toxins were purchased from Biozol
Diagnostica, Germany).
The KOR agonist DynA, the µ-opioid receptor
(MOR) agonist [D-Ala2, N-MePhe4, Gly-ol]-enkephalin
(DAMGO), and the δ-opioid receptor (DOR) agonist
SNC-80 were applied at a concentration of 500 nM (all
from Tocris). The KOR antagonist GNTI (5′-Guanidinyl-17-
(cyclopropylmethyl)-6,7-dehydro-4,5α-epoxy-3,14-dihydroxy-6,
7-2′,3′-indolomorphinan dihydrochloride; Tocris) was applied
prior to DynA at a concentration of 1.5 µm. The
κ-opioid receptor 1 (KOR1) agonist U69,593((+)-(5α,7α,8β)-
N-Methyl-N-[7-(1-pyrrolidinyl)-1-oxaspiro[4.5]dec-8-yl]-benze
neacetamide; Sigma Aldrich) and the KOR2 agonist GR
89696 fumarate (4-[(3,4-Dichlorophenyl)acetyl]-3-(1-pyrroli
dinylmethyl)-1-piperazinecarboxylic acid methyl ester fumarate,
Tocris) were bath-applied at a concentration of 250 nM. For
co-application of DynA and CRF (Tocris), both drugs were
used at a concentration of 250 nM. The CRF receptor 1
(CRF1) antagonist antalarmin hydrochloride (Tocris) was
used at a concentration of 4 µm. Tertiapin Q (Tocris), an
antagonist of ROMK1 and GIRK1/4 potassium channels,
was bath-applied at a concentration of 200 nM. In some
experiments, 0.5 µm BaCl2 was added to the aCSF. When
using BaCl2, MgSO4 was replaced by 1.5 mM MgCl2 in the
aCSF.
Voltage-Clamp Ramps
To analyze the nature of substance-induced currents,
depolarizing voltage-clamp ramps were performed (from
−120 to −20 mV; 3 s) from a holding potential of −60 mV.
The recordings were done in presence of 1 µm TTX to reduce
network activity and 100 µm CdCl2 to reduce calcium currents
during depolarizing ramps. Ramps were recorded during
baseline conditions (Rampbaseline) and during maximal drug
effect (Rampdrug). The resultant, substance-induced current
was calculated by Rampdrug − Rampbaseline and plotted vs. the
holding potential.
Evoked Inhibitory Postsynaptic Currents
(eIPSCs)
To evoke GABAA receptor (GABAAR)-mediated postsynaptic
currents in NPS neurons, a tungsten bipolar stimulation
electrode was placed rostral to the NPS neurons in the periLC.
NPS neurons were recorded in voltage-clamp mode at a holding
potential of −65 mV using a KCl-based intracellular solution.
Recordings were done in presence of AMPA, NMDA and
GABAB receptor antagonists. The latency was measured between
the stimulation artifact and the onset of the postsynaptic
responses. Responses with latencies <5 ms were accepted for
analysis. Evoked inhibitory postsynaptic currents (eIPSCs) were
considered as failures when it lacked typical IPSC kinetics and
when the amplitude was smaller than two times the standard
deviation of the mean baseline noise. Brief (50–100 µs) electrical
pulses were delivered with an interstimulus interval of 20 s. The
stimulation strength was set to allow failures in the majority of
recordings during baseline stimulation.
Miniature Inhibitory Postsynaptic Currents
(mIPSCs)
The miniature IPSCs (mIPSCs) were recorded in the voltage-
clamp mode at a holding potential of −65 mV using a high
chloride intracellular solution, containing 105mMKCl instead of
K-gluconate. To block AP triggered release, 0.5 µm tetrodotoxin
was added to the aCSF. DNQX, AP-5, and CGP55845
were added to the aCSF to antagonize AMPA-, NMDA-,
and GABAB receptor-mediated currents, respectively, and to
record pharmacologically isolated GABAAR-mediated mIPSCs.
Neurons were allowed to equilibrate for at least 5 min prior to
recordings. Frequency, amplitudes and kinetics of mIPSCs, rise
time10–90% and decay time90–10%, were automatically analyzed
during baseline conditions and in presence of DynA using
Clampfit10.
Statistics
Data are represented as box plots, in which the box represents
the first (25%) and third (75%) quartiles, the band represents
the median, and the whiskers represent the percentiles 5% and
95%. The square within the box represents the mean. All data sets
were tested for statistically significant outliers using the Grubbs’
test (significance level p < 0.05). Within group comparisons
were done by using a paired student’s t-test (significance level
∗p < 0.05; ∗∗p < 0.01). To analyze differences between different
groups, one-way ANOVA followed by Bonferroni post hoc test or
unpaired student’s t-test were used (significance level ∗p < 0.05;
∗∗p< 0.01).
RESULTS
Gene expression profiling of isolated NPS neurons from the
periLC of NPS-EGFP mice indicates the expression of KORs in
these neurons (Liu et al., 2011). Furthermore, it has previously
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FIGURE 1 | Effects of opioid receptor agonists on the membrane potential of NPS neurons. (A,B) Sample current-clamp recordings of NPS neurons in the
periLC region. Hyperpolarizing current pulses (−50 pA; 500 ms) were applied to monitor the input resistance of the recorded neuron. While application of 250 nM
DynA induced a transient hyperpolarization (A), the kappa opioid receptor (KOR) antagonist GNTI hydrochloride prevented the DynA effect (B). To monitor
drug-induced changes in input resistance, the membrane potential was manually set to baseline values by adjusting a DC offset during maximal drug effect (transient
jump in membrane potential seen in A). This allows distinguishing between direct drug-induced changes in input resistance and indirect changes induced by
voltage-dependent conductances. (C) Quantification of the effect of DynA on the membrane potential in the absence (n = 14) or presence of GNTI hydrochloride
(n = 5). (D) Quantification of the mean membrane potential shift following application of 250 nM DynA (n = 14), 500 nM DAMGO (n = 9) and 500 nM SNC-80 (n = 9).
(E) Time course of the membrane potential changes in response to DynA/CRF co-application in absence (black) or presence (gray) of the corticotropin-releasing
factor receptor 1 (CRF1) antagonist antalarmin. Inset shows a sample recording in current-clamp mode. (F) Quantification of the membrane potential changes in
NPS neurons during DynA/CRF co-application (n = 5) and DynA/CRF co-application in presence of antalarmin (n = 5).
been shown that the neuropeptides DynA and somatostatin
hyperpolarize NPS neurons in the periLC region (Jüngling
et al., 2015). To reveal detailed information on the underlying
cellular mechanisms and the specificity of the DynA application
and the subsequent activation of KORs, EGFP-expressing NPS
neurons (here referred to as NPS neurons) were recorded in
the whole-cell current-clamp mode at a membrane potential
set around −65 mV. In the presence of glutamate and GABA
receptor antagonists, and 0.5µmTTX, the application of 250 nM
DynA induced a significant membrane hyperpolarization in
all neurons tested (n = 14; Figures 1A,C). In agreement with
previous results, the average membrane potential (Vm) of NPS
neurons during baseline conditions was at –67.9 ± 1.1 mV
and shifted to –77.6 ± 1.4 mV in the presence of DynA
(∆Vm = –9.5 ± 1.0 mV; p = 6.806E-7; t = 9.42; DoF = 12;
Figure 1D). The DynA-induced hyperpolarization was absent
in the presence of the KOR antagonist GNTI (1.5 µm; n = 5;
Figures 1B,C). The membrane potential was at –64.9 ± 1.0 mV
in the presence of GNTI and at –64.8 ± 1.0 mV in the
presence of GNTI and DynA (∆Vm = 0.14 ± 0.68 mV). GNTI
alone had no significant effect on the membrane potential
of NPS neurons (One-Way analysis of variance [ANOVA]:
F(3,32) = 21.7; post hoc test: GNTI vs. GNTI/DynA: p = 1;
baseline vs. DynA: p = 4.37E-6; DynA vs. GNTI/DynA:
p = 6.065E-6; baseline vs. GNTI: p = 1; DynA vs. GNTI:
p = 7.368E-6; Figures 1B,C). These data indicate that DynA
hyperpolarizes NPS neurons in the periLC via activation of
KORs.
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In a next set of experiments, the specific MOR and DOR
agonists DAMGO and SNC-80, respectively, were bath-applied
during current-clamp recordings. Neither 500 nM DAMGO
(Vm = –63.1 ± 1.3 mV vs. baseline Vm = –63.4 ± 1.4 mV;
∆Vm = −0.28 ± 0.61 mV, n = 9; p = 0.663; t = −0.453;
DoF = 8), nor 500 nM SNC-80 (Vm = –63.7± 1.4 mV vs. baseline
Vm = –63.7± 1.0 mV;∆Vm = –0.06± 0.77 mV; n = 9; p = 0.944;
t = 0.072; DoF = 8) changed the Vm of NPS neurons (Figure 1D).
The ∆Vm induced by DynA was significantly different from
the ∆Vm induced by DAMGO or SNC-80 (One-way ANOVA
F(2,28) = 43.3; p = 2.704E-9; post hoc test: DynA vs. DAMGO:
p = 3.593E-8; DynA vs. SNC-80: p = 6.949E-8; DAMGO vs.
SNC-80: p = 1; Figure 1D). These data indicate that NPS neurons
at the periLC are responsive to KOR activation, but do not
respond to MOR or DOR agonists.
As previously reported, NPS neurons in the periLC depolarize
following activation of CRF1 (Jüngling et al., 2012). Since DynA
and CRF can be coexpressed in LC afferents (Reyes et al.,
2008; for review, see Van Bockstaele et al., 2010), we tested
the effect of co-application of DynA and CRF (250 nM each)
on the membrane potential of NPS neurons in the periLC.
Under current-clamp conditions at a membrane potential of
−65 mV (−64.1 ± 0.9 mV) in presence of 1 µm TTX, the
co-application induced a hyperpolarization (−69.9 ± 3.3 mV)
followed by a prominent depolarization (−56.2 ± 3.3 mV)
upon wash (One-Way ANOVA: F(2,12) = 33.06; p = 1.313E-5;
post hoc test: baseline vs. DynA/CRF: p = 0.014; baseline vs. wash:
p = 0.002; DynA/CRF vs. wash: p = 9.893E-6; n = 5; Figures 1E,F).
Co-application of DynA and CRF in the presence of the CRF1
antagonist antalarmin (4 µm) induced a more prominent and
longer lasting hyperpolarization and abolished the depolarization
during wash (One-Way ANOVA: F(2,12) = 22.7;post hoc test:
baseline vs. DynA/CRF: p = 9.258E-5; baseline vs. wash:
p = 0.416; DynA/CRF vs. wash: 0.001; n = 5; Figures 1E,F). The
DynA/CRF-induced hyperpolarization was significantly larger in
presence of antalarmin (∆Vm: −11.9 ± 1.7 mV) compared to
recordings without antalarmin (∆Vm: −5.9 ± 1.2 mV; unpaired
t-test: p = 0.022; t = −2.84; DoF = 8). These findings indicate
that the dynorphin and the CRF system interact at the level of
single NPS neurons and induce a biphasic change in membrane
potential in these cells.
In order to analyze the effect of DynA on active and passive
membrane properties of NPS neurons, current-clamp recordings
in the absence of TTX were done (Figures 2A,B). Hyper- and
depolarizing current injections (500 ms duration; from −80
to +100 pA; ∆I +10 pA) were delivered during current-clamp
recordings at a membrane potential of −60 mV under baseline
conditions and in presence of 250 nM DynA (Figures 2A,B).
In the presence of DynA, the shift of the membrane potential
in response to hyperpolarizing currents was significantly less
FIGURE 2 | KOR activation by DynA reduces the excitability of NPS neurons. (A) Passive membrane responses to hyperpolarizing current injections
(−80 to 0 pA; ∆I +10 pA; 500 ms duration) in absence and presence of 250 nM DynA (n = 14). In presence of DynA, NPS neurons showed reduced voltage
deflections in response to hyperpolarizing current injections. (B) Quantification of passive membrane responses to hyperpolarizing current injections. (C) Active
membrane responses of NPS neurons to increasing depolarizing current injections (0–90 pA; ∆I +10 pA; 500 ms duration). Application of 250 nM DynA reduced the
number of action potentials (APs) generated in response to the injected current. (D) Quantification of active membrane responses to depolarizing current injections.
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TABLE 1 | Summary of passive and active membrane properties recorded
in the current-clamp mode at a membrane potential of −60 mV during
baseline and in presence of DynA (n = 14).
Baseline DynA
Mean SEM Mean SEM p-value
Rin [M] 629 51 431 43 0.01
Tau [ms] 38.2 1.9 32.7 3.3 0.17
Threshold [mV] −41.2 0.6 −38.9 1.0 0.06
AP amplitude [mV] 73.7 0.7 68.4 0.9 0.03
AHP [mV] 17.6 0.6 18.8 0.5 0.15
Half-width [ms] 1.2 0.1 1.1 0.1 0.31
slAHP [mV] 3.1 0.5 1.4 0.3 0.01
Amplitudelast [mV] 53.7 2.2 53.3 2.8 0.92
AHPlast [mV] 17.0 0.9 18.8 0.7 0.13
Inst. frequency [Hz] 34.8 1.7 28.7 2.5 0.06
Time to 1st AP [ms] 12.2 0.8 14.0 1.3 0.25
Significant changes are marked in bold. Differences with a strong trend, but not
reaching the p < 0.05 significance criteria are marked in italic.
at all tested currents (Figures 2A,C). These data indicate that
DynA induces a reduction in input resistance, which is in line
with previous observations (Jüngling et al., 2015). Additionally,
in the presence of DynA, NPS neurons generated fewer APs in
response to depolarizing current injections, reaching significance
for all tested current injections from +30 pA on (Two-Way
ANOVA with repeated measurements: F(9,252) = 10.04; there
is a significant difference between baseline and DynA: p <
0.0001; levels of significance for the post hoc test are indicated
in the Figure 2D). A summary of other active and passive
membrane properties analyzed during baseline conditions and
in presence of DynA is given in Table 1 (n = 14). In summary,
DynA reduces the input resistance and excitability of NPS
neurons.
Ionic Mechanisms Underlying
DynA-Induced Hyperpolarization
In order to reveal the ionic mechanisms underlying the
hyperpolarization of NPS neurons following KOR activation,
whole-cell voltage-clamp recordings were performed at a holding
potential of −60 mV in presence of DNQX, AP-5, GBZ,
CGP55845, and TTX (Figure 3A). In voltage-clamp mode,
250 nM DynA induced an outward current of 34.9 ± 4.7 pA
(n = 5). The current amplitude was dose-dependent (50 nM:
11.5 ± 4.6 pA, n = 4; 100 nM: 12.6 ± 2.6 pA, n = 3;
200 nM: 31.5 ± 6.4 pA, n = 6; 250 nM: 37.2 ± 4.2 pA, n = 9;
500 nM: 38.3 ± 4.5 pA, n = 8; Figure 4B). The dose-response
curve indicates that 250 nM DynA induced a near-maximal
activation of KORs, since 500 nM DynA did not induce a larger
current (Figure 3B).
To identify the DynA-induced current, a voltage-clamp ramp
protocol (−120 to −20 mV, 3 s, 60 s inter-trial interval)
was applied during baseline conditions and in the presence of
DynA (Figure 3C). The DynA-induced current was calculated
by subtraction of the currents during baseline conditions
from those recorded in the presence of DynA (Figure 3D),
and current-voltage (I-V) relations were constructed. DynA
induced an outward current that reversed at −106.5 ± 4.6 mV
(n = 5), a value close to the estimated potassium equilibrium
potential for the present recording conditions (−109 mV). In
addition, the DynA-induced current displayed slight inward
rectification. To test a possible effect of DynA on adenylyl
cyclase-dependent pathways, 150 µm 8-Br-cAMP, which clamps
the intracellular cAMP level at a high level, was included in
the recording pipette during voltage-clamp recordings. The
inclusion of 8-Br-cAMP reduced the DynA-induced outward
current in NPS neurons without reaching statistical significance
(DynA-induced current in control: 37.2 ± 4.2 pA; n = 9; DynA-
induced current in presence of 8-Br-cAMP: 19.6 ± 6.3; n = 4;
Figure 3F), suggesting that the observed current is mediated
in parts via a down-regulation of AC activity. Furthermore,
a cesium-methanesulfonate based intracellular solution (Cs-
met) abolished the DynA-induced current completely (DynA-
induced current with Cs-met: −6.7 ± 3.5 pA; n = 4), providing
further evidence for involvement of potassium conductances
following KOR stimulation. Blocking ROMK1 and GIRK1/4
potassium channels by adding 200 nM tertiapin Q reduced
the DynA-induced current to 10.6 ± 4.8 pA (n = 8;
Figures 3E,F). The DynA-induced current was completely
abolished in 0.5 µm BaCl2, which blocks a broad spectrum of
inwardly rectifying potassium channels (DynA-induced current
in BaCl2: −2.1 ± 5.9 pA, n = 6; Figures 3E,F; One-Way
ANOVA: F(4,26) = 12.67; p = 7.497E-6; post hoc test: DynA
control vs. CsCl2: p = 5.283E-5; DynA control vs. tertiapin
Q: p = 0.002; DynA control vs. BaCl2: p = 3.907E-5). These
data provide evidence that the DynA-induced current is
mediated by inwardly rectifying potassium channels and that
the majority of these channels are tertiapin Q-sensitive GIRK1/4
channels.
DynA Negatively Modulates GABAergic
Transmission
In a next set of experiments, the AP-dependent release of GABA
was investigated by analyzing electrically evoked IPSCs (eIPSCs)
in NPS neurons. The stimulation electrode was positioned
rostro-laterally to the NPS neuron cluster (Figure 4A). The
eIPSCs appeared as inward currents and were sensitive to the
GABAAR antagonist GBZ (n = 3; Figure 4B). The eIPSCs had
a mean amplitude of –122 ± 31 pA with a failure rate of
11.2 ± 2.9% (n = 11). Application of 250 nM DynA reduced
normalized mean eIPSC amplitudes to 0.53 ± 0.07. This effect
was completely reversed upon wash out of DynA. At the
end of the recording, the amplitude of eIPSCs recovered to
0.99 ± 0.18 of baseline (One-Way ANOVA: F(2,30) = 0.008;
post hoc test: baseline vs. DynA: p = 0.019; baseline vs. wash:
p = 1; wash vs. DynA: p = 0.019; n = 11; Figures 4C,D).
The failure rate of eIPSCs increased from 11.5 ± 2.7% during
baseline conditions to 43.2 ± 9.2% in presence of DynA and
reversed to 12.5 ± 4.2% after wash out of DynA (One-Way
ANOVA: F(2,29) = 8.67; p = 0.001; post hoc test: baseline
vs. DynA: p = 0.003; baseline vs. wash: p = 1; wash vs.
DynA: p = 0.005; Figure 4D). Neither the mean latency of
the eIPSCs (baseline: 2.2 ± 0.2 ms; DynA: 2.3 ± 0.2 ms),
nor the eIPSC kinetics such as rise time10–90% or decay time
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FIGURE 3 | Ionic mechanisms underlying the DynA-induced hyperpolarization. (A) Example of NPS neuron recorded in the voltage-clamp mode at a holding
potential of −60 mV. Application of 250 nM DynA induces a transient, outward directed current. The gap in the trace indicates the time point of a voltage-clamp
ramp recording during DynA application. (B) Dose-response relationship of the DynA-induced outward current in response to 50 nM (n = 4), 100 nM (n = 3), 200 nM
(n = 6), 250 nM (n = 9) and 500 nM (n = 8) DynA. Dotted lines represent the upper and lower confidence interval (95% level). (C) Sample voltage-clamp ramp
recording (−120 mV to −20 mV, 3 s, 60 s inter-trial interval) during baseline (black) and in presence of DynA (gray). (D) Example of a DynA-induced current calculated
from the voltage-clamp ramps shown in (C). The mean DynA-induced current reversed at −106.5 ± 4.6 mV (n = 5). (E) Example recordings of the DynA-induced
current with inclusion of either 8-Br-cAMP or Cs-met in the internal recording solution or in presence of either 200 nM tertiapin Q or 0.5 µm BaCl2. (F) Quantification
of the DynA-induced current during control conditions (n = 9), in the presence of 8-Br-cAMP (n = 4), Cs-met-sulfonate (n = 4), tertiapin Q (n = 8) or BaCl2 (n = 6).
constant τ were significantly altered by DynA (rise time baseline:
1.2 ± 0.1 ms, DynA: 1.4 ± 0.2 ms; decay time constant
baseline: 13.3 ± 0.7 ms, DynA: 14.6 ± 0.9 ms; Figure 4E).
These data provide evidence that DynA negatively affects the
efficacy of evoked GABAergic synaptic transmission onto NPS
neurons.
To identify the possible site of action (pre- or postsynaptic)
of the dynorphin system on GABAergic transmission, mIPSC in
NPS neurons were recorded in voltage-clamp mode at a holding-
potential of –65 mV and in presence of 0.5µmTTX (Figure 5A).
The mIPSC frequency was 2.5 ± 0.2 Hz (n = 8) during baseline
recordings. The application of 250 nMDynA induced a reduction
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FIGURE 4 | DynA reduces the efficacy of GABAergic synapses on NPS neurons. (A) Scheme of the stimulation electrode position and recording site in a
horizontal slice preparation of a transgenic nps-enhanced green fluorescent protein (EGFP) mouse. NPS neurons are located close to the fourth ventricle (4th V) next
to the locus coeruleus (LC). The stimulation electrode was placed rostrally to the recording site. (B) Evoked GABAergic postsynaptic responses (black) were sensitive
to the GABAAreceptor (GABAAR) antagonist gabazine (GBZ). (C) Examples of electrically evoked IPSCs (eIPSCs) during baseline, in presence of 250 nM DynA and
after wash. The mean response is presented in gray. (D) Quantification of the mean normalized success amplitudes and failure rate of the eIPSCs (n = 11).
(E) Quantification of the eIPSC latency, rise time10–90% and decay time constant during baseline and in presence of DynA.
in mIPSC frequency to 1.0± 0.2 Hz, which reversed to 1.6± 0.2
after wash (One-Way ANOVA: F(2,21) = 15.8; p = 6.485E-5;
post hoc test: baseline vs. DynA: p = 4.753E-5; baseline vs. wash:
p = 0.0071; wash vs. DynA: p = 0.1395; n = 8; Figures 5A,B).
The mean amplitude of the mIPSCs during baseline recordings
was −101 ± 8.8 pA. Application of DynA slightly reduced the
amplitude to−87± 6.8 pA, which remained at 87.1± 8 pA after
wash (One-Way ANOVA: F(2,21) = 1.06; p = 0.364; Figure 5C).
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FIGURE 5 | DynA reduces the frequency of miniature inhibitory
postsynaptic currents (mIPSCs) in NPS neurons. (A) Sample
voltage-clamp recording of mIPSCs in an NPS neuron at a holding potential of
−65 mV during baseline conditions and in presence of DynA. Quantification of
the normalized frequency (B) and normalized amplitudes (C) of mIPSCs
during baseline, in presence of DynA and after wash (n = 10). (D) Examples of
mean mIPSCs recorded during baseline conditions and in presence of DynA.
(E) Application of DynA affects neither rise time nor decay time constants of
mIPSCs.
DynA did not affect the mIPSC kinetics (rise time10–90% and
decay time90–10%), which were extracted from thirty averaged
events during baseline and DynA application (Figure 5D). The
rise time was 1.8 ± 0.2 ms under control conditions and
1.8 ± 0.2 ms in presence of DynA (p = 0.71; t = 0.394; DoF = 7;
n = 8), and the decay time90–10% was 27.3± 1.0 ms under control
conditions and 26.9 ± 1.2 ms in presence of DynA (p = 0.55;
t = 0.63; DoF = 7; n = 8; Figure 5E). The fact that DynA mainly
affected the frequency of mIPSCs points to an involvement of
presynaptic mechanisms.
Differential Distribution of KOR1 and KOR2
Receptors
At least two KOR subtypes, KOR1 and KOR2, can be
differentiated pharmacologically (Zukin et al., 1988). Here, we
used the KOR1 agonist U69,593 and the KOR2 agonist GR89696
(both at a concentration of 250 nM) to pharmacologically analyze
the functional expression profile of these two receptor subtypes
pre- and postsynaptically. During recordings of the membrane
potential in presence of TTX, DNQX, CGP55845, GBZ andAP-5,
U69,593 induced a significant hyperpolarization of NPS neurons
(Figure 6A). The NPS neurons hyperpolarized from−61± 1mV
during baseline recordings to −67.4 ± 0.6 mV (p = 9.815E-
4; t = 5.98; DoF = 6 n = 7; Figure 6A). In contrast, GR89696
failed to induce a significant hyperpolarization (baseline:
−62.1 ± 0.4 mV; GR89696: −63.0 ± 1.1 mV; p = 0.33;
t = 1.02; DoF = 11; n = 12; Figure 6A). The maximal
shift of the membrane potential (∆Vmembrane) was significantly
larger upon U69,593 application (−7.0 ± 1.2 mV) compared
to the ∆Vmembrane induced by GR89696 (−1.0 ± 0.9 mV;
p = 2.005E-4; t = −4.71; DoF = 17; Figure 6B). These data
indicate that NPS neurons express KOR1, but not KOR2
postsynaptically.
Conversely, both, the KOR1 and KOR2 agonists, modulated
the frequency of mIPSCs recorded from NPS neurons in the
periLC region (Figure 7A). The KOR1 agonist U69,593 reduced
the mIPSC frequency from 2.3 ± 0.3 Hz during baseline
recordings to 1.2 ± 0.3 Hz (1.4 ± 0.3 Hz after wash; One-
Way ANOVA: F(2,21) = 4.14; p = 0.031; post hoc test: baseline
vs. U69,593: p = 0.0397; baseline vs. wash: p = 0.118; wash
vs. U69,593: p = 1; n = 8; Figure 7B). The mIPSC amplitude
decreased from −106 ± 13 pA to −74 ± 8 pA in presence
of U69,593 (−81 ± 7 pA after wash; One-Way ANOVA:
F(2,21) = 3.28; p = 0.058; Figure 7C). Similarly, the KOR2 agonist
GR89696 induced a decrease in frequency from 1.9 ± 0.2 Hz
during baseline to 1.1 ± 0.2 Hz (1.3 ± 0.2 Hz after wash;
One-Way ANOVA: F(2,18) = 4.84; p = 0.021; post hoc test:
baseline vs. GR89696: p = 0.019; baseline vs. wash: p = 0.25;
wash vs. GR89696: p = 0.68; n = 7; Figure 7B). The amplitudes
shifted from −115 ± 14 pA during baseline to −98 ± 13 pA
and −102 ± 14 pA in presence of GR89696 and after wash,
respectively (One-Way ANOVA: F(2,18) = 0.95; p = 0.4; n = 7;
Figure 7C). In summary, both, KOR1 and KOR2 agonists, affect
the frequency ofmIPSCs, indicating a presynaptic mode of action
of both pharmacologically distinct receptor subtypes.
DISCUSSION
The NPS system has been shown to be anxiolytic (Xu et al., 2004;
Jüngling et al., 2008; Meis et al., 2008) and to attenuate stress-
induced impairment of fear extinction (Chauveau et al., 2012).
NPS neurons in the periLC depolarize in response to CRF
application and subsequent CRF1 receptor activation (Jüngling
et al., 2012). Moreover, stress exposure increases the expression
Frontiers in Cellular Neuroscience | www.frontiersin.org 9 March 2016 | Volume 10 | Article 61
Jüengling et al. Neuropeptide S and Dynorphin
FIGURE 6 | The κ-opioid receptor 1 (KOR1) agonist U69,593 mimics the effect of DynA on the membrane potential of NPS neurons. (A) Effect of the
KOR1 agonist U69,593 (250 nM; n = 7) and the KOR2 agonist GR89696 (250 nM; n = 12) on the membrane potential of NPS neurons. (B) Quantification of the
effects of KOR1 and KOR2 agonists on the membrane potential. Note the lack of effect of the KOR2 agonist GR89696.
FIGURE 7 | Both, KOR1 and KOR2 agonists, reduce the frequency of mIPSCs in NPS neurons. (A) Examples of mIPSCs recorded during baseline
conditions and in presence of U69,593 (left) or GR89696 (right) in the voltage-clamp mode at a holding potential of −65 mV. Quantification of the normalized
frequency (B) and normalized amplitudes (C) during baseline conditions, in presence of U69,593 (n = 7) or GR89696 (n = 7), and after wash.
of the immediate early gene cfos in NPS neurons (Jüngling et al.,
2012), andNPS levels are increased during stressful encounters in
the basolateral amygdala in vivo (Ebner et al., 2011). These data
strongly suggest that the NPS system is active during stressful
experiences. Conversely, there is evidence that a variety of stress
effects, such as aversion and depressive-like effects are mediated
by the kappa opioid system (Mague et al., 2003; McLaughlin
et al., 2003; Smith et al., 2012; Van Bockstaele et al., 2010).
Additionally, interference with the kappa opioid system by KOR
antagonists reduces anxiety-like behavior (Knoll et al., 2007,
2011; Wittmann et al., 2009).
While the gene expression profile of NPS neurons in the
periLC indicates the presence of KORs as well as DORs and
MORs (Liu et al., 2011), only the endogenous KOR ligand
DynA but neither a specific MOR nor a specific DOR agonist
induced a strong hyperpolarization of the membrane potential
of NPS neurons. Using membrane potential as read out of
receptor stimulation, these data indicate that, in contrast to
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KORs,MORs andDORs are not expressed postsynaptically in the
NPS neurons. This conclusion does not exclude the possibility
that MORs and DORs are functionally expressed at presynaptic
sites.
The data presented here provide evidence that NPS neurons
are inhibited following KOR activation. Conversely, NPS
neurons are activated by the activation of CRF1 by either CRF
or stressin I (Jüngling et al., 2012). Since DynA and CRF
are co-expressed e.g., in LC projecting neurons of the central
amygdala (Reyes et al., 2011), both substances might be co-
released. Co-application of DynA and CRF induced a biphasic
response in NPS neurons, displaying a hyperpolarization
followed by a depolarization upon wash. These data indicate
that DynA is apt to attenuate CRF-induced activation of NPS
neurons. Contrariwise, CRF diminishes the DynA-dependent
hyperpolarization.
Application of DynA decreased the excitability and the
input resistance of NPS neurons. Both effects seem to be
mediated by an increase in the potassium conductance. It has
previously been shown that KORs are intracellularly linked to
inhibitory Gi/o-proteins (Law et al., 2000), and activate inwardly
rectifying potassium channels (GIRK; Henry et al., 1995). The
DynA-induced outward current displayed rectifying properties
and was sensitive to Cs+ in the internal solution, strongly
arguing for an activation of potassium conductances in NPS
neurons in response to DynA. The inclusion of cAMP in
the intracellular solution did not significantly alter the DynA-
induced current, excluding a potential role of adenylyl cyclases
which has been observed in other types of neurons (Attali et al.,
1989; Lawrence and Bidlack, 1993). Moreover, in presence of
barium, the DynA-induced current was abolished, arguing for
a major contribution of inwardly rectifying potassium channels.
Of the four G protein-coupled inwardly rectifying potassium
channel subunits (GIRK1–4) expressed in the rodent brain
(Kobayashi et al., 1995; Karschin et al., 1996), the subunits
GIRK1 and GIRK4 are sensitive to tertiapin Q, whereas GIRK2
and GIRK3 are insensitive (Jin et al., 1999). The DynA-induced
current in NPS neurons was significantly reduced in presence of
tertiapin Q, indicating the activation of GIRK1/4 downstream
of the KOR. As seen in the box plots (Figure 3F), the DynA-
induced currents were not abolished in all recorded neurons,
pointing to the expression of tertiapin Q-insensitive GIRKs.
In addition, G protein signaling beyond the canonical seven
transmembrane domain receptors and G protein-independent
pathways of these receptors may exist, including roles in receptor
tyrosine kinase signaling and activity of G-protein accessory
proteins (Sun et al., 2007; Coulon et al., 2010;Marty and Ye, 2010;
Sato and Ishikawa, 2010).
Pharmacologically, two KORs, KOR1 and KOR2, can be
distinguished by the use of specific agonists (Nock et al., 1988;
Zukin et al., 1988; Rothman et al., 1989; Butelman et al., 2001).
The KOR1-specific agonist U69,593, but not the KOR2 agonist
GR89696, mimicked the hyperpolarizing effect of DynA in
NPS neurons. A similar differential effect of KOR1 and KOR2
receptors has been described in proopiomelanocortin neurons
(POMC) in the arcuate nucleus where KOR2 agonists but
not KOR1 agonists induce a GIRK-dependent outward current
(Zhang and van den Pol, 2013). Taken together, DynA induces a
hyperpolarization and decreases the excitability of NPS neurons
via KOR1.
The kappa opioid system has been shown to negatively
regulate the release of GABA from synapses in various neuronal
circuits (Hjelmstad and Fields, 2001, 2003; Li et al., 2012). During
local electrical stimulation of GABAergic inputs onto NPS
neurons in the periLC, application of DynA induced a significant
increase in the failure rate of the evoked release. Concomitantly,
a clear trend towards a transiently decreased mean amplitude of
evoked IPSCs was observed. In contrast, the kinetic of eIPSCs was
largely unaffected. Moreover, DynA and the KOR1- and KOR2-
specific agonists, U69,593 and GR89696, respectively, reduced
the frequency of GABAergic mIPSCs recorded in the presence of
TTX. These data indicate that KORs can reduce GABA release
by a presynaptic mode of action. From our data it cannot be
concluded whether KOR1 and KOR2 receptors are expressed
in the same or in separated synaptic terminals. It is known
that there is formation of heterodimers of G protein-coupled
receptors, which affects receptor pharmacology and signaling
of the interacting subtypes (Prinster et al., 2005). Whether or
not such an interaction of KOR1 and KOR2 plays a role in
GABAergic afferents to NPS neurons in the periLC should be
investigated in future studies.
It has previously been shown that the KOR1 agonist
U69,593 attenuates GABA release by a reduction of the
presynaptic Ca2+ influx via N-type channels (Hjelmstad and
Fields, 2003). Effects of DynA on the frequency of GABAergic
IPSCs have also been described for POMC and neuropeptide
Y neurons in the arcuate nucleus (Zhang and van den Pol,
2013). Thus, it seems that mainly presynaptic mechanisms
contribute to the observed reduction of the GABAergic
synaptic transmission by KOR agonists. This would imply
that KOR1 and KOR2 are present at presynaptic terminals
of GABAergic synapses, whereas only KOR1 mediates the
observed hyperpolarization via a direct postsynaptic mechanism.
The activation of either presynaptic or postsynaptic located
KORs could have differential effects on the excitability of NPS
neurons. Activation of somatic KORs, inducing a prominent
hyperpolarization, most likely would inactivate NPS neurons,
and subsequently would cease the release of glutamate and
NPS in the target regions of these neurons. Conversely, a
predominant KOR activation on GABAergic terminals could
mediate a disinhibition of NPS neurons due to a reduction of
GABA release. Dynorphin could also act in an autoinhibitory
mode since GABAergic afferents to NPS neurons in the periLC
can contain dynorphin (Jüngling et al., 2015). In this scenario,
heavily active GABAergic terminals control the amount of
GABA release by co-releasing dynorphin. The net effect of KOR
activation, either pre- and/or postsynaptically, on NPS neurons
in the periLC in vivo remains elusive and demands further
investigation.
Dynorphin-containing afferents can arise from various brain
regions such as the hypothalamic paraventricular nucleus (PVN;
Watson et al., 1983; Reyes et al., 2005), the bed nucleus of the
stria terminalis (BNST; Van Bockstaele et al., 1999b), the nucleus
of the solitary tract (NTS; Van Bockstaele et al., 1999a) or the
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central nucleus of the amygdala (CeA; Reyes et al., 2008, 2011).
These brain regions send afferents to neurons of the LC and
are involved in stress responses. Recently, neurons of the CeA
expressing prodynorphin and/or somatostatin have been shown
to form GABAergic synapses onto NPS neurons in the periLC
(Jüngling et al., 2015), bringing them into the ideal position to
counteract the activity of NPS neurons during stress exposure
or anxiety. Based on these findings, it is tempting to speculate
that anxiolytic-like effects in rats upon KOR antagonism (Knoll
et al., 2007) are influenced by a disinhibition of the NPS system
and/or a more pronounced CRF effect on NPS neurons in
absence of KOR activity. Since the NPS system is present in
a variety of brain regions and modulates different cognitive
and autonomic states, the interaction of the dynorphinergic
and the NPS system can be manifold and demands further
investigation. To date it is unclear during which conditions
(relevant stressor or phasic vs. chronic stress) KORs in NPS
neurons are activated. In conclusion, our data provide evidence
indicating that the NPS and the kappa opioid system are
interacting and that the endogenous opioid dynorphin is suited
to inhibit NPS neurons at the LC. In turn, NPS release in
putative target regions will decrease during opioid-mediated
inactivation of NPS neurons, exerting a variety of physiological
consequences such as increased anxiety or vulnerability to stress
exposure.
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